These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29032659)

  • 1.
    Birhanu BT; Lee SJ; Park NH; Song JB; Park SC
    J Vet Sci; 2018 Mar; 19(2):188-199. PubMed ID: 29032659
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of drug target candidates of the swine pathogen Actinobacillus pleuropneumoniae by construction of protein-protein interaction network.
    Li S; Su Z; Zhang C; Xu Z; Chang X; Zhu J; Xiao R; Li L; Zhou R
    Genes Genomics; 2018 Aug; 40(8):847-856. PubMed ID: 30047117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Construction and characterization of Actinobacillus pleuropneumoniae serovar 7 live attenuated vaccine strain co-expressing ApxIA].
    Liu J; Chen Y; Hu L; Bei W; Chen H
    Sheng Wu Gong Cheng Xue Bao; 2010 Mar; 26(3):305-10. PubMed ID: 20518341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Actinobacillus pleuropneumoniae vaccines: from bacterins to new insights into vaccination strategies.
    Ramjeet M; Deslandes V; Gouré J; Jacques M
    Anim Health Res Rev; 2008 Jun; 9(1):25-45. PubMed ID: 18346296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuated Actinobacillus pleuropneumoniae double-deletion mutant S-8∆clpP/apxIIC confers protection against homologous or heterologous strain challenge.
    Xie F; Li G; Zhou L; Zhang Y; Cui N; Liu S; Wang C
    BMC Vet Res; 2017 Jan; 13(1):14. PubMed ID: 28061786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs.
    Shin MK; Kang ML; Jung MH; Cha SB; Lee WJ; Kim JM; Kim DH; Yoo HS
    Vet Immunol Immunopathol; 2013 Jan; 151(1-2):132-9. PubMed ID: 23206402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actinobacillus pleuropneumoniae biofilms: Role in pathogenicity and potential impact for vaccination development.
    Hathroubi S; Loera-Muro A; Guerrero-Barrera AL; Tremblay YDN; Jacques M
    Anim Health Res Rev; 2018 Jun; 19(1):17-30. PubMed ID: 29110751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of metabolic adaptation and biofilm formation of Actinobacillus pleuropneumoniae field isolates from the upper and lower respiratory tract of swine with respiratory disease.
    Aper D; Frömbling J; Bağcıoğlu M; Ehling-Schulz M; Hennig-Pauka I
    Vet Microbiol; 2020 Jan; 240():108532. PubMed ID: 31902502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responses of pigs to a re-challenge with Actinobacillus pleuropneumoniae after being treated with different antimicrobials following their initial exposure.
    Sjölund M; de la Fuente AJ; Fossum C; Wallgren P
    Vet Rec; 2009 May; 164(18):550-5. PubMed ID: 19411684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drug resistance marker in the pigs.
    Bei W; He Q; Zhou R; Yan L; Huang H; Chen H
    Vet Microbiol; 2007 Nov; 125(1-2):120-7. PubMed ID: 17580102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of proteins of Propionibacterium acnes for use as vaccine candidates to prevent infection by the pig pathogen Actinobacillus pleuropneumoniae.
    Li L; Sun C; Yang F; Yang S; Feng X; Gu J; Han W; Langford PR; Lei L
    Vaccine; 2013 Oct; 31(45):5269-75. PubMed ID: 24051157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae.
    Antenucci F; Fougeroux C; Deeney A; Ørskov C; Rycroft A; Holst PJ; Bojesen AM
    Vet Res; 2018 Jan; 49(1):4. PubMed ID: 29316978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AasP autotransporter protein of Actinobacillus pleuropneumoniae does not protect pigs against homologous challenge.
    Oldfield NJ; Worrall KE; Rycroft AN; Ali T; Wooldridge KG; Ala'Aldeen DA
    Vaccine; 2009 Aug; 27(38):5278-83. PubMed ID: 19563888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive role for rApxIVN in the immune protection of pigs against infection by Actinobacillus pleuropneumoniae.
    Wang C; Wang Y; Shao M; Si W; Liu H; Chang Y; Peng W; Kong X; Liu S
    Vaccine; 2009 Sep; 27(42):5816-21. PubMed ID: 19654060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
    Maas A; Meens J; Baltes N; Hennig-Pauka I; Gerlach GF
    Vaccine; 2006 Nov; 24(49-50):7226-37. PubMed ID: 17027123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial resistance, biofilm formation and virulence reveal Actinobacillus pleuropneumoniae strains' pathogenicity complexity.
    Pereira MF; Rossi CC; Seide LE; Martins Filho S; Dolinski CM; Bazzolli DMS
    Res Vet Sci; 2018 Jun; 118():498-501. PubMed ID: 29758533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial resistance genes in Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida isolated from Australian pigs.
    Dayao D; Gibson JS; Blackall PJ; Turni C
    Aust Vet J; 2016 Jul; 94(7):227-31. PubMed ID: 27349882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model.
    Chiang CH; Huang WF; Huang LP; Lin SF; Yang WJ
    Vaccine; 2009 Jul; 27(34):4565-70. PubMed ID: 19520199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoplasmic glycoengineering of Apx toxin fragments in the development of Actinobacillus pleuropneumoniae glycoconjugate vaccines.
    Passmore IJ; Andrejeva A; Wren BW; Cuccui J
    BMC Vet Res; 2019 Jan; 15(1):6. PubMed ID: 30606265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal immunization with major epitope-containing ApxIIA toxin fragment induces protective immunity against challenge infection with Actinobacillus pleuropneumoniae in a murine model.
    Seo KW; Kim SH; Park J; Son Y; Yoo HS; Lee KY; Jang YS
    Vet Immunol Immunopathol; 2013 Jan; 151(1-2):102-12. PubMed ID: 23200821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.